Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males
NCT00480467
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Interventions
DRUG:
SAM-315
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer